Who are AAV2-GDNF gene therapy's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): NurOwn® (MSC-NTF cells), p53 gene therapy, voretigene neparvovec-rzyl, rAd-p53 gene, Onasemnogene Abeparvovec-xioi, p53 with chemotherapy.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aav2-gdnf-gene-therapy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

AAV2-GDNF gene therapy — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AAV2-GDNF gene therapy (AAV2-GDNF gene therapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: gene therapy. Area: Neurology.

phase 2 gene therapy GDNF Neurology Biologic Live · refreshed every 30 min

Target snapshot

AAV2-GDNF gene therapy (AAV2-GDNF gene therapy) — Brain Neurotherapy Bio, Inc.. AAV2-GDNF gene therapy delivers a viral vector carrying the GDNF gene to the brain, where it is expressed and promotes the survival and growth of dopaminergic neurons.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AAV2-GDNF gene therapy TARGET	AAV2-GDNF gene therapy	Brain Neurotherapy Bio, Inc.	phase 2	gene therapy	GDNF
NurOwn® (MSC-NTF cells)	NurOwn® (MSC-NTF cells)	Brainstorm-Cell Therapeutics	phase 3	Cell therapy	Neurotrophic factors (NGF, BDNF, GDNF)
p53 gene therapy	p53 gene therapy	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy	p53 (tumor suppressor protein)
voretigene neparvovec-rzyl	voretigene neparvovec-rzyl	Spark Therapeutics, Inc.	marketed	Gene therapy	RPE65 gene
rAd-p53 gene	rAd-p53 gene	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy; oncolytic virus	p53 tumor suppressor gene
Onasemnogene Abeparvovec-xioi	Onasemnogene Abeparvovec-xioi	Novartis Gene Therapies	marketed	Gene therapy	SMN1 gene
p53 with chemotherapy	p53 with chemotherapy	Shenzhen SiBiono GeneTech Co.,Ltd	marketed	Gene therapy; recombinant adenovirus vector	p53 (tumor suppressor protein)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (gene therapy class)

Brain Neurotherapy Bio, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AAV2-GDNF gene therapy — Competitive Intelligence Brief. https://druglandscape.com/ci/aav2-gdnf-gene-therapy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab